Resonant Surgical Secures Tens of Millions in Series A Funding to Advance High-End Surgical Devices
On March 20, Kunshan Leisheng Medical Technology Co., Ltd. (hereinafter referred to as “Leisheng Medical”) announced the completion of its Series A financing round, raising tens of millions of yuan. The investors in this round were Jiuyou Capital and Xingze Capital. The funds raised will be primarily used for the research and development of high-end surgical medical devices.
LeiSheng Medical, founded in 2017, is a company dedicated to the development and commercialization of forward-looking active surgical devices. It currently focuses on radiofrequency ablation product lines and integrated ultrasonic surgical instruments targeting the high-end niche market. The integrated ultrasonic surgical instruments developed by LeiSheng Medical offer extended service life and high performance, combining the advantages of both corded and cordless devices. This represents a cutting-edge international trend and a significant market opportunity.
Chen Haigang, Partner at Xingze Capital, an investor in this round, stated: “LeiSheng Medical’s radiofrequency ablation product portfolio, represented by its vascular radiofrequency ablation devices, has met and surpassed international leading brands across multiple functional and performance metrics, including procedural control, safety profile, control precision, and accuracy of impedance and temperature sensing. This positions the company to achieve import substitution for a series of active surgical instruments.”
Sun Yi, Executive Partner at Jiuyou Capital, stated, “The domestic high-end active medical device market is currently still dominated by imported products. Chinese manufacturers are continuously strengthening their R&D capabilities to catch up with international standards. Leisheng Medical is undoubtedly one of the outstanding domestic players. Through innovative product design and stringent quality control, Leisheng is poised to provide Chinese surgeons with a superior surgical experience and offer cost-effective products and services to the general public in the near future.”
It is reported that before founding Leisheng Medical, Dr. Tan Wei led innovative R&D projects at several internationally renowned medical device corporations. He participated in and oversaw the research and development of more than 20 medical products, developed multiple industry-leading products, and was the first to propose the concept of a universal broadband active surgical platform, successfully translating it into commercialized products.
An innovative product faces numerous challenges from the proposal of its theoretical foundation to the development of a reliable final product. In the medical device industry, the productization phase is fraught with unfavorable factors, including high technical risks, long development cycles, and substantial capital investment, resulting in an even lower “survival rate.” Dr. Tan Wei’s R&D project experience encompasses the entire lifecycle, from initial theory to final product commercialization, which has endowed Leisheng Medical’s product development with the following two characteristics:
Certainty-Driven Innovation: Product innovation backed by robust engineering capabilities, keeping risks firmly under control. The team has extensive experience in developing several world-class me-too products, allowing R&D activities to build upon the shoulders of giants;
Universal Platform, Niche Applications: The company’s core technologies enable energy-based devices with ultra-wide bandwidth and dynamic range control, allowing a single universal platform to support multiple niche applications with specialized requirements. This capability is underpinned by platform-based instrument technology centered on electronics and software, as well as consumable production technology for niche applications that leverages clinical expertise and specialized manufacturing processes.
By breaking through traditional barriers while leveraging the continuity and heritage derived from industry accumulation, Leisheng Medical achieved remarkable R&D outcomes within a short period at the very inception of its venture.
Tan Wei stated, “The high-end medical device sector is a specialized industry with strong reliance on its supply chain. Over the past decade, the Yangtze River Delta region has developed a comprehensive industrial chain. Like our many diligent small and medium-sized enterprise (SME) suppliers, our dream is to leverage our talent and dedication to serve China’s rapidly transforming market and contribute our share.”